Michael Lee Milligan sold $5,119 of NMRA
See Remarks at Neumora Therapeutics, Inc.. 1,436 shares at an average of $3.57, traded Feb 17, 2026, filed Feb 19, 2026.
Score components
- +15RoleOfficer
- 0Trade size$5k at market
- 0Share of holdings soldSold 6.4% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001610717-26-000051, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | SOpen-market sale Common Stock10b5-1 | -1,436 | $3.57 | $5,119 | 21,034 | Feb 19, 2026 |
Related signals
Other insiders at Neumora Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Neumora Therapeutics, Inc. | Daljit Singh Aurora See Remarks | $22k 6,165 shares | -7% | |
| 36Weak | Neumora Therapeutics, Inc. | Paul L Berns See Remarks | $34k 9,819 shares | -0% | |
| 35Weak | Neumora Therapeutics, Inc. | Joshua Pinto President | $21k 5,967 shares | -9% | |
| 29Weak | Neumora Therapeutics, Inc. | Daljit Singh Aurora See Remarks | $307k 114,703 shares | -100% | |
| 61Notable | Neumora Therapeutics, Inc. | ARCH Venture Partners X, LLC owner | $5.0M 1,915,700 shares | +46% | |
| 61Notable | Neumora Therapeutics, Inc. | ARCH Venture Partners XII, LLC owner | $5.0M 1,915,700 shares | +46% | |
| 69Notable | Neumora Therapeutics, Inc. | Kristina Burow director, owner | $5.0M 1,915,700 shares | +46% | |
| 3Weak | Neumora Therapeutics, Inc. | Daljit Singh Aurora Chief Strategy Officer | $14k 8,565 shares | -9% | |
| 3Weak | Neumora Therapeutics, Inc. | Paul L Berns See Remarks | $23k 13,871 shares | -0% | |
| 23Weak | Neumora Therapeutics, Inc. | Matthew K Fust director | $371k 21,788 shares | -78% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.